JLE

European Journal of Dermatology

MENU

Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis Volume 22, issue 3, May-June 2012

Figures

See all figures

Authors
Dermatology Unit,, Pediatric Dermatology Unit, University of Padua Via C. Battisti 206, 35128, Padova, Italy

ejd.2012.1704 Auteur(s) : Edoardo Zattra1, Anna Belloni Fortina2, Mauro Alaibac1 mauro.alaibac@unipd.it 1 Dermatology Unit, 2 Pediatric Dermatology Unit, University of Padua Via C. Battisti 206, 35128, Padova, Italy Eruption and/or excess of multiple melanocytic nevi has been reported to occur in patients treated with immunosuppressive drugs or chemotherapy [1]. Natalizumab (Tysabri™, Dompè Biogen) is a humanized monoclonal antibody against the cellular adhesion molecule alpha4-integrin, used to [...]